Table 1 Predominant serotypes among enterovirus infection patients with severe complications and deaths
From: The secular trend of enterovirus A71 after the implementation of preventive measures in Taiwan
Year | Predominant Serotype Circulating in The Community | Case Number of Enterovirus Infection Patients with Severe Complications | Predominant Serotypes in Enterovirus Infection Patients with Severe Complications | Number of Deaths | Predominant Serotype in the Deceased | Severe case fatality rate |
|---|---|---|---|---|---|---|
1998 | NA | 405 | EV71 | 78 | EV71 | 19.30% |
1999 | NA | 35 | Cox B3 | 9 | Cox B3 | 25.7% |
2000 | NA | 291 | EV71 | 41 | EV71 | 14.1% |
2001 | Cox A16 EV71 | 393 | EV71 | 58 | EV71 | 14.8% |
2002 | ECHO6 | 162 | EV71 | 30 | EV71 | 18.5% |
2003 | Cox A16 | 70 | EV71 | 9 | EV71 | 12.9% |
2004 | Cox A4 | 50 | EV71 | 5 | EV71 | 10% |
2005 | Cox B3 | 142 | EV71 | 16 | EV71 | 11.3% |
2006 | Cox A2 | 11 | EV71 | 0 | – | 0% |
2007 | Cox A6 | 12 | EV71 | 3 | EV71 | 25% |
2008 | Cox A2 | 373 | EV71 | 14 | EV71 | 3.8% |
2009 | Cox A6 | 29 | EV71 | 2 | EV71 | 6.9% |
2010 | Cox A16 | 16 | EV71 | 0 | – | 0% |
2011 | Cox A10 | 59 | EV71 | 4 | EV71 | 6.8% |
2012 | EV71 | 153 | EV71 | 2 | EV71 | 1.3% |
2013 | Cox A6 | 12 | EV71 | 1 | ECHO30 | 8.3% |
2014 | Cox A10 | 6 | Cox A | 1 | ECHO11 | 16.7% |
2015 | Cox A16 | 6 | Cox B5 | 2 | Cox A16 Cox B5 | 33.3% |
2016 | Cox A10 | 33 | EV71 | 1 | EV71 | 3% |
2017 | Cox A4 Cox A6 | 24 | EVD68 | 1 | CoxB3 | 4.2% |
2018 | Cox A10 | 36 | ECHO11 | 8 | ECHO11 | 22% |
2019 | Cox A10 | 69 | EV71 | 4 | EV71 | 5.8% |
2020 | Cox A6 | 6 | EV71 | 0 | – | 0% |